Parallel Advisors LLC Takes $283,000 Position in Esperion Therapeutics Inc (NASDAQ:ESPR)

Parallel Advisors LLC purchased a new stake in Esperion Therapeutics Inc (NASDAQ:ESPR) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 7,710 shares of the biopharmaceutical company’s stock, valued at approximately $283,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Russell Investments Group Ltd. boosted its stake in Esperion Therapeutics by 4,267.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 29,962 shares of the biopharmaceutical company’s stock valued at $1,100,000 after purchasing an additional 29,276 shares during the period. California Public Employees Retirement System boosted its stake in Esperion Therapeutics by 43.9% during the 3rd quarter. California Public Employees Retirement System now owns 46,113 shares of the biopharmaceutical company’s stock valued at $1,691,000 after purchasing an additional 14,066 shares during the period. Virginia Retirement Systems ET AL boosted its stake in Esperion Therapeutics by 168.1% during the 3rd quarter. Virginia Retirement Systems ET AL now owns 12,600 shares of the biopharmaceutical company’s stock valued at $462,000 after purchasing an additional 7,900 shares during the period. Bailard Inc. boosted its stake in Esperion Therapeutics by 19.3% during the 3rd quarter. Bailard Inc. now owns 90,900 shares of the biopharmaceutical company’s stock valued at $3,332,000 after purchasing an additional 14,700 shares during the period. Finally, Rhenman & Partners Asset Management AB boosted its stake in Esperion Therapeutics by 59.2% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 655,854 shares of the biopharmaceutical company’s stock valued at $24,044,000 after purchasing an additional 243,761 shares during the period.

Shares of ESPR stock traded up $0.25 during midday trading on Friday, reaching $37.82. 592,400 shares of the company were exchanged, compared to its average volume of 500,623. The company’s 50 day moving average price is $38.49 and its two-hundred day moving average price is $42.58. Esperion Therapeutics Inc has a 12 month low of $33.13 and a 12 month high of $58.90. The company has a market cap of $1.11 billion, a P/E ratio of -5.02 and a beta of 1.86. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.65 and a current ratio of 5.65.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($2.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.95) by ($0.42). The company had revenue of $0.98 million for the quarter, compared to analysts’ expectations of $0.99 million. During the same quarter in the previous year, the firm earned ($1.86) earnings per share. As a group, sell-side analysts predict that Esperion Therapeutics Inc will post -3.02 earnings per share for the current year.

A number of research analysts have issued reports on the stock. Northland Securities reissued a “buy” rating on shares of Esperion Therapeutics in a research note on Thursday, August 29th. BidaskClub raised shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 29th. Goldman Sachs Group raised shares of Esperion Therapeutics from a “sell” rating to a “neutral” rating and reduced their target price for the company from $55.00 to $45.00 in a research note on Monday, September 16th. Stifel Nicolaus reduced their target price on shares of Esperion Therapeutics from $112.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, September 17th. Finally, Cowen restated a “buy” rating on shares of Esperion Therapeutics in a research report on Wednesday. One research analyst has rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $70.44.

In other Esperion Therapeutics news, CEO Timothy M. Mayleben bought 2,500 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was bought at an average cost of $35.25 per share, with a total value of $88,125.00. Following the completion of the transaction, the chief executive officer now directly owns 76,015 shares of the company’s stock, valued at approximately $2,679,528.75. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Target N. V. Biotech bought 75,000 shares of the firm’s stock in a transaction on Wednesday, November 6th. The stock was acquired at an average cost of $37.30 per share, with a total value of $2,797,500.00. Following the completion of the transaction, the insider now directly owns 3,727,964 shares of the company’s stock, valued at $139,053,057.20. The disclosure for this purchase can be found here. Insiders have purchased 167,500 shares of company stock worth $5,943,925 over the last ninety days. 7.70% of the stock is currently owned by insiders.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

See Also: Death Cross

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.